Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | FADS1 | O60427 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5852993 | 1.00 | TSHR (0.54) | TSHRTAAR1PARP1HTR2AHTR2C | |
| SCHEMBL16412704 | 1.00 | TSHR (0.54) | TSHRTAAR1PARP1HTR2AHTR2C | |
| SCHEMBL25831541 | 1.00 | TSHR (0.54) | TSHRTAAR1PARP1HTR2AHTR2C | |
| SCHEMBL21974861 | 0.84 | TSHR (0.67) | TSHRPARP1 | |
| SCHEMBL46283 | 0.84 | TSHR (0.67) | TSHRPARP1 | |
| SCHEMBL13262751 | 0.82 | TAAR1 (0.41) | TSHRTAAR1PARP1HTR2AHTR2C | |
| SCHEMBL12186555 | 0.80 | DRD2 (0.49) | TSHRTAAR1PARP1HTR2AHTR2C | |
| SCHEMBL15161596 | 0.80 | DRD2 (0.49) | TSHRTAAR1PARP1HTR2AHTR2C | |
| SCHEMBL2599512 | 0.80 | DRD2 (0.49) | TSHRTAAR1PARP1HTR2AHTR2C | |
| SCHEMBL12186467 | 0.80 | DRD2 (0.49) | TSHRTAAR1PARP1HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115927276-A | Halogen alcohol dehalogenase mutant and application thereof in synthesizing chiral oxazolidinone | 中国科学院天津工业生物技术研究所 | 2023-04-07 | — | — | CN | claimed |
| US-20260042758-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2026-02-12 | — | — | US | disclosed |
| EP-4688738-A1 | HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688742-A1 | CYCLOHEXYL OR HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4651867-A1 | BETA 2-ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OR PREVENTION OF MUSCLE WASTING | Atrogi AB (SE) | 2025-11-26 | — | — | EP | disclosed |
| US-12280023-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2025-04-22 | — | — | US | disclosed |
| CN-119662579-A | Styrene monooxygenase mutant and application thereof | 中国科学院成都生物研究所 | 2025-03-21 | — | — | CN | disclosed |
| US-20240390298-A1 | CYCLOHEXYL BETA-HYDROXY ALKYL AMINES AND MEDICAL USES THEREOF | ATROGI AB (SE) | 2024-11-28 | — | — | US | disclosed |
| EP-4463453-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024200768-A1 | CYCLOHEXYL OR HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA | ATROGI AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| EP-0611826-A2 | Processes for production of optically active epoxides | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-24 | — | — | EP | disclosed |
| EP-0589484-A1 | 1,2-Ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-03-30 | — | — | EP | disclosed |
| EP-0587194-A1 | 2-(Heterocycloalkoxy)-1-(subst.-phenyl)-ethanol derivatives as cerebral function improving agents | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-03-16 | — | — | EP | disclosed |
| EP-0587193-A1 | 1,2-Ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-03-16 | — | — | EP | disclosed |
| US-5280032-A | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1994-01-18 | — | — | US | disclosed |
| US-5017619-A | Anitdiabetic | HOFFMANN-LA ROCHE INC. (US) | 1991-05-21 | — | — | US | disclosed |
| EP-0383281-A1 | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same | TOYAMA CHEMICAL CO., LTD. (JP) | 1990-08-22 | — | — | EP | disclosed |
| US-4621150-A | METAL PERHALATE OR SULFONATE OR COMPLEX; GLYCIDATE, 2-HYDROXY-3-BUTENOATE, EPOXIDE | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1986-11-04 | — | — | US | disclosed |
| EP-0153692-A2 | Method for isomerization a glycidate derivative | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1985-09-04 | — | — | EP | disclosed |
| US-4005212-A | ANTIDEPRESSANT, ANOREXIGENIC, PSYCHOENERGIZING, 2-PHENYL-2,3,5,6-TETRAHYDROIMIDAZO(2,1-B)THIAZOLE | RHONE-POULENC S.A. (FR) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390298-A1 | CYCLOHEXYL BETA-HYDROXY ALKYL AMINES AND MEDICAL USES THEREOF | H1-5, CYP3A5, HRH3 | TSHR 2693/4885TAAR1 437/4885PARP1 926/4885 |
| US-20260042758-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | BRAF, RAF1, NRAS | TSHR 929/4885TAAR1 1237/4885PARP1 1999/4885 |
| US-12280023-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | GPR119, SLC5A2, SLC5A1 | TSHR 1556/4885TAAR1 1115/4885PARP1 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.